solvent B over 40 min with 0.1% TFA/H 2 O as solvent A and 90% MeCN/0.1% TFA/H 2 O as solvent B on either a Vydac analytical C4 column (214TP54; 5 µm, 4.6 mm x 250 mm) or a Vydac analytical C18 column (218TP54; 5 µm, 4.6 mm x 250 mm). Purification was carried out by preparative RP-HPLC using a Waters Delta 600 system with a 10 mL/min flow rate.
Compounds were detected at 230 nm. Separations were performed with solvent A and solvent B on either a Vydac preparative C4 column (214TP1022; 10 µm, 22 mm x 250 mm) or a Vydac preparative C18 column (218TP1022; 10 µm, 22 mm x 250 mm). A Zetasizer Nano ZP instrument (Malvern Instruments, UK) with DTS software was used for particle size measurements. Sizes were analysed using a non-invasive backscatter system. Measurements were taken at 25 °C with scattering angle of 173° using disposable cuvettes. Transmission electron microscopy was performed on a JEM-1010 transmission electron microscope (JEOL Ltd., Japan) operated at 100 kV. The sample images were taken and analyzed using the AnalySIS ® software (Soft Imaging Systems, Megaview III, Munster, Germany).
Peptide azide 1
Azide derivative of FNBR-B epitope (VETEDTKEPG VLMGGQSESV EFTKDTQTGM) was prepared using HBTU/DIPEA Fmoc-SPPS. Peptide 1 was synthesized on rink amide The azido acetic acid was coupled using HBTU/DIPEA at room temperature (2 x 2 hours).
The cleavage of 1 from the resin was carried out in the solution of TFA/triisopropylsilane/water in ratio 95/2.5/2.5 for 4 hours. The product was purified by preparative RP-HPLC on C18 column with solvent gradient 0%-50% solvent B over 50 min. 
LCP construct 5
Compound 5 was synthesized according to the procedure described in the main text. HPLC analysis (C4 column): t R = 27.2 min, purity > 95%. Compound 5 Compound 6
